This week, we will discuss the use of 3K dialysis bath with sodium zirconium cyclosilicate versus 2K bath and no potassium lowering medications in dialysis patients and the associated risk of arrhythmia.
This week, we will discuss post-trial follow-up for EMPA-Kidney. What are the longer-term effects of empagliflozin for patients with chronic kidney disease?
Nausea is a very common and distressing problem. Some medications that treat nausea carry a higher risk for arrhythmias, like Torsades de Pointes, and sudden cardiac death. Is ondansetron safe for use in patients on hemodialysis?
This week, we will discuss non-steroidal mineralocorticoid antagonist in the multiverse of cardiovascular-kidney-metabolic. What FINEHEART pooled analysis would add to what we already learned from FIDELIO-DKD trial?
We will be discussing the DIABOLO trial of acetazolamide to shorten mechanical ventilation. The Tuesday chat will be at 9PM EDT and the Wednesday chat will be at 8PM London, Noon PDT.
The article can be found at the JAMA website or via Pubmed.
Take a look at Joel's summary of the article.
See this summary by The Bottom Line
Coverage by MedPage Today
